Five experts from the Division of Hematology presented highlights and updates from the 61^st Annual American Society of Hematology Annual Meeting and Exposition, which was held in December 2019. This annual review seeks to ensure that clinical providers throughout the Rocky Mountain region remain well-informed about the latest treatment advancements in benign and malignant hematology so that they may continue to advocate for the best possible outcomes for their patients.

Myeloproliferative Neoplasms | Brandon McMahon, MD

Benign Hematology | Tyler Buckner, MD

Acute Myeloid Leukemia/Myelodisplastic Syndrome | Dan Pollyea, MD

Plasma Cell Disorders from Tomer Mark, MD:

"The findings from major studies in multiple myeloma reported at ASH 2019 were presented and discussed.  Disease areas discussed included newly diagnosed myeloma for both fit and frail patients, relapsed and refractory myeloma, and smoldering myeloma."

Lymphomas from Manali Kamdar, MD:

"For patients with limited stage Diffuse Large B-Cell Lymphoma (DLBCL), RCHOPx4 is now the standard of care."

"CAR T Cell therapy continues to look very promising with the availability of three constructs."

"Post CAR T failure patients now have a ray of hope with a new immunotherapy BITE molecule called mosenutuzumab."

Benign Hematology from Tyler Buckner, MD, MSc:

"Gene therapy technology is moving forward rapidly, with multiple products aiming to treat several hematologic conditions expected to reach the US market in the near future. 

Individuals with sickle cell anemia, beta thalassemia, hemophilia A and hemophilia B have been treated in gene therapy clinical trials, and many have had life-improving responses to the treatments. Long-term follow up for patients who receive gene therapy will be important, and the hematology field will need to learn to adjust how we care for these individuals who no longer have to live with a lifelong chronic disease."

AML/MDS from Dan Pollyea, MD:

"Our understanding of AML is rapidly increasing, and with this, advances in the treatment of this disease are being made."

In addition to the presentations, attendees conversed with local experts over breakfast and lunch, met with members of the Hematology Clinical Trials Unit (HCTU) about their current and upcoming clinical studies, and chatted with pharmaceutical representatives about their efforts in providing the most effective and highest quality drugs.

Attendees conversing over breakfast.

GOLD SPONSOR:

GOLD SPONSOR:

SILVER SPONSOR: